These data highlight the need to better investigate and validate the potential value of CSF levels of IL-9, which could be then used as prognostic biomarker of a specific MS endophenotype with better disease outcome and as marker to monitor responses to therapies. This evidence concerns the gene IL9 and myeloid sarcoma.